溶瘤病毒疗法市场－全球产业规模、份额、趋势、机会及预测（按病毒类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球溶瘤病毒疗法市场预计将从 2025 年的 4,973 万美元成长到 2031 年的 1.5331 亿美元，复合年增长率为 20.64%。

这个专门的癌症治疗领域利用天然或基因工程改造的病毒，这些病毒旨在选择性地复製并摧毁恶性细胞，同时诱导广泛的抗肿瘤免疫反应。推动该市场发展的关键因素包括难治性癌症发生率的上升以及临床上迫切需要毒性低于传统疗法的标靶治疗。此外，基因改造技术的不断进步使得开发具有更高特异性和效力的病毒成为可能，进一步促进了相关研发工作。

根据美国基因与细胞治疗学会2024年的数据，全球基因、细胞和RNA疗法的开发平臺超过4,000个，这数字显示目前大量投资正涌入溶瘤病毒等先进治疗方法。儘管发展势头强劲，但市场成长仍面临宿主免疫系统的重大挑战。预先存在的免疫反应以及人体对病毒的快速清除，可能导致治疗在有效清除靶向癌细胞之前就失效，从而对疗效构成重大挑战。

市场驱动因素

推动全球溶瘤病毒疗法市场发展的主要因素是全球癌症和固态肿瘤负担的日益加重，这使得临床上迫切需要能够克服晚期疾病中常见的抗药性的药物。美国癌症协会在2025年1月发布的《2025年癌症事实与数据》报告中预测，到2025年，美国新增癌症病例将达到2,041,910例，凸显了日益严重的疾病负担。患者数量的增加促使大规模资本投资涌入，旨在加速药物研发管线的开发。例如，Labiotech.eu在2025年8月报道称，Tilt Biotherapeutics于2025年5月完成了2,500万美元的B轮资金筹措，用于进一步开发其候选药物TILT-123。这显示业界正致力于利用新型病毒製剂来满足这些临床需求。

同时，协同联合治疗的日益普及正在重塑市场格局，尤其是溶瘤病毒与查核点抑制剂的联合疗法。这些病毒正被越来越多地用于改变肿瘤微环境，从而有效提高免疫「冷」肿瘤对查核点阻断疗法的敏感性。这项策略得到了令人信服的临床数据支持。根据Replimune集团2025年6月发布的题为「Replimune公布最新分析结果」的新闻稿，RP1与Nivolumab联合治疗在接受抗PD-1治疗失败的黑色素瘤患者中实现了75.3%的1年生存率。如此强劲的结果支持了这些联合治疗的商业性和治疗潜力，并推动其被纳入未来的标准肿瘤治疗通讯协定。

市场挑战

宿主免疫系统构成了一道强大的生物屏障，显着阻碍了溶瘤病毒疗法的疗效和商业性进程。当治疗性病毒被注射到体内时，患者的先天性和适应性免疫系统通常会将其识别为病原体，并迅速产生中和抗体。这种免疫反应往往会在病毒能够在肿瘤内充分复製或诱导预期肿瘤溶解之前将其从体内清除，导致临床疗效不稳定，并降低了整体治疗方法的可靠性。

这项挑战直接阻碍了市场成长，导致临床开发阶段的高脱落率，并需要高成本大量时间和成本进行研究。将有前景的临床前结果转化为核准疗法的困难，造成了产品平臺的重大瓶颈，后期成功案例远少于早期阶段的案例便印证了这一点。根据再生医学联盟2024年的报告，预计全球仅有17个项目将接近监管部门的核准。如此有限的候选药物即将上市，凸显了早期病毒清除等生物学障碍如何限制了全球溶瘤病毒疗法市场的扩充性和获利能力。

市场趋势

该领域的显着成熟体现在病毒载体平台已不再局限于单纯疱疹病毒（HSV）。研发人员正积极探索具有独特免疫抗原性原性的替代载体，例如腺病毒和痘苗病毒。这种转变使得针对特定肿瘤类型客製化病毒载体平台成为可能，从而克服了第一代疗法的局限性。这些非HSV载体平台的商业性可行性得到了可靠的后期临床数据支持。根据Kandel Therapeutics公司于2025年3月发布的“2024年第四季度及全年财务业绩”，该公司基于腺病毒的候选药物CAN-2409已在一项涉及496名患者的3期临床试验中得到评估，这表明该公司明确致力于拓展其病毒载体疗法的种类。

同时，为了克服肿瘤内注射的局限性，人们正转向全身静脉注射机制，这为转移性疾病的治疗开启了新的可能性。新一代病毒平台旨在能够在血液中存活，逃避中和作用，并主动标靶化转移性肿瘤部位。这种从局部到全身给药的转变显着扩大了目标患者群体，并使病毒疗法与标准的肿瘤输注流程相容。根据Oncolytics Biotech公司于2024年12月发布的「Oncolytics Biotech 2024财年业绩亮点」新闻稿，在BRACELET-1试验中，静脉注射Pelareorep与单独化疗相比，预计可使患者的中位总生存期延长一年以上，这支持了全身病毒给药的治疗效果。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球溶瘤病毒疗法市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依病毒类型（基因改造溶瘤病毒、野生型溶瘤病毒）
  • 依应用领域（肺癌、乳癌、结肠癌、黑色素瘤、摄护腺癌、头颈癌、卵巢癌、胰臟癌、其他癌症）
  • 按最终使用者（医院/诊所、癌症研究中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美溶瘤病毒疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲溶瘤病毒疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区溶瘤病毒疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲溶瘤病毒疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲溶瘤病毒疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球溶瘤病毒疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Immunocore Holdings plc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Oncolytic Virotherapy Market is projected to expand from USD 49.73 Million in 2025 to USD 153.31 Million by 2031, registering a CAGR of 20.64%. This specialized field of cancer treatment utilizes native or genetically engineered viruses designed to selectively replicate within and destroy malignant cells while simultaneously triggering a wider antitumor immune response. Major factors driving this market include the rising incidence of refractory cancers and the urgent clinical need for targeted therapies that offer lower toxicity than conventional treatments. Additionally, ongoing advancements in genetic modification techniques are enabling the creation of viruses with greater specificity and potency, further fueling development efforts.

According to data from the 'American Society of Gene & Cell Therapy' in '2024', the global pipeline for gene, cell, and RNA therapies included over 4,000 active candidates, a figure that highlights the massive investment currently flowing into advanced modalities such as oncolytic viruses. Despite this strong momentum, market growth faces a substantial hurdle in the form of the host immune system. Preexisting immunity or the body's rapid clearance of the virus can neutralize the therapy before it has the opportunity to effectively eliminate the targeted tumor cells, posing a significant challenge to efficacy.

Market Driver

The primary engine propelling the Global Oncolytic Virotherapy Market is the escalating global burden of cancer and solid tumors, which creates an acute clinical need for agents capable of overcoming the resistance often seen in late-stage disease. The 'American Cancer Society' projected in its 'Cancer Facts & Figures 2025' report (January 2025) that there would be 2,041,910 new cancer cases in the United States in 2025, underscoring the intensifying disease burden. This increasing patient volume has triggered substantial financial investments aimed at accelerating pipeline development; for example, Labiotech.eu reported in August 2025 that Tilt Biotherapeutics secured a $25 million Series B financing round in May 2025 to advance its candidate TILT-123, demonstrating the industry's dedication to meeting these clinical needs with novel viral agents.

Simultaneously, the market landscape is being reshaped by the growing adoption of synergistic combination therapies, particularly those pairing oncolytic viruses with checkpoint inhibitors. These viruses are increasingly used to modify the tumor microenvironment, effectively sensitizing immunologically cold tumors to checkpoint blockade. This strategy is supported by compelling clinical data; according to a June 2025 press release titled 'Replimune Presents New Analyses' by Replimune Group, Inc., the combination of RP1 and nivolumab resulted in a 75.3% 1-year overall survival rate in patients with anti-PD1 failed melanoma. Such robust results validate the commercial and therapeutic potential of these combination regimens, driving their incorporation into future standard oncology protocols.

Market Challenge

The host immune system represents a formidable biological barrier that significantly hinders the efficacy and commercial advancement of oncolytic virotherapy. When therapeutic viruses are administered, the patient's innate and adaptive immune systems often recognize them as pathogens, rapidly generating neutralizing antibodies. This immune response frequently clears the virus from the body before it can sufficiently replicate within the tumor or induce the intended oncolysis, leading to inconsistent clinical results and undermining the overall reliability of the therapy.

This challenge directly stifles market growth by causing high attrition rates during clinical development and necessitating prolonged, expensive research cycles. The difficulty in translating promising preclinical findings into approved therapies creates a severe bottleneck in the product pipeline, evidenced by the low number of late-stage successes compared to early-stage activity. According to the 'Alliance for Regenerative Medicine' in '2024', the sector expected only '17 programs' to near regulatory approval globally. This limited volume of near-market candidates highlights how biological hurdles, such as premature viral clearance, restrict the scalability and revenue potential of the global oncolytic virotherapy market.

Market Trends

A significant maturation in the sector is marked by the diversification of viral platforms beyond Herpes Simplex Virus, as developers increasingly explore alternative vectors like adenovirus and vaccinia for their unique immunogenic profiles. This shift enables the tailoring of viral backbones to specific tumor types, addressing the limitations associated with first-generation therapies. The commercial viability of these non-HSV platforms is supported by robust late-stage data; according to Candel Therapeutics in March 2025 regarding their 'Fourth Quarter and Full Year 2024 Financial Results', the company's adenovirus-based candidate, CAN-2409, was evaluated in a Phase 3 arm of 496 patients, demonstrating a clear clinical focus on expanding the repertoire of viral modalities.

Concurrently, there is a transition toward systemic intravenous delivery mechanisms to overcome the limitations of intratumoral injection, thereby opening new possibilities for treating metastatic disease. Next-generation viral platforms are being engineered to survive in the bloodstream, evade neutralization, and actively target disseminated tumor sites. This evolution from local to systemic administration significantly broadens the addressable patient population and aligns virotherapy with standard oncology infusion workflows. As reported by Oncolytics Biotech in December 2024 in their 'Oncolytics Biotech Highlights 2024 Achievements' press release, the intravenous administration of pelareorep in the BRACELET-1 study yielded an estimated median overall survival benefit exceeding one year compared to chemotherapy alone, confirming the therapeutic viability of systemic viral delivery.

Key Market Players

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Immunocore Holdings plc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.

Report Scope

In this report, the Global Oncolytic Virotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncolytic Virotherapy Market, By Virus Type

• Genetically Engineered Oncolytic Virus
• Oncolytic Wild Type Virus

Oncolytic Virotherapy Market, By Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head and Neck Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Others

Oncolytic Virotherapy Market, By End User

• Hospitals & Clinics
• Cancer Research Centers
• Others

Oncolytic Virotherapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncolytic Virotherapy Market.

Available Customizations:

Global Oncolytic Virotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncolytic Virotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Virus Type (Genetically Engineered Oncolytic Virus, Oncolytic Wild Type Virus)
  • 5.2.2. By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Cancer Research Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Oncolytic Virotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Virus Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oncolytic Virotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Virus Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Oncolytic Virotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Virus Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Oncolytic Virotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Virus Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Oncolytic Virotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Virus Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oncolytic Virotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Virus Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Oncolytic Virotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Virus Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Oncolytic Virotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Virus Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Oncolytic Virotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Virus Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Oncolytic Virotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Virus Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Oncolytic Virotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Virus Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oncolytic Virotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Virus Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Oncolytic Virotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Virus Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Oncolytic Virotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Virus Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Oncolytic Virotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Virus Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Oncolytic Virotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Virus Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Oncolytic Virotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Virus Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Oncolytic Virotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Virus Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Oncolytic Virotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Virus Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Oncolytic Virotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Virus Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Oncolytic Virotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Virus Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Oncolytic Virotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Virus Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Oncolytic Virotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Virus Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Oncolytic Virotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Virus Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Oncolytic Virotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. GlaxoSmithKline plc
• 15.4. Immunocore Holdings plc.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. AstraZeneca
• 15.7. Merck & Co., Inc.
• 15.8. Boehringer Ingelheim GmbH
• 15.9. Bristol-Myers Squibb Company
• 15.10. Johnson & Johnson Services, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer